InsiderTrades

Form 4 for ZBIO Zenas BioPharma, Inc.

Accepted 2024-09-16 00:00:00 ET · period of report 2024-09-12 · accession 0001104659-24-100325 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-09-16 2024-09-16 ZBIO MOULDER LEON O JR CEO, Dir C - Cnv Deriv — +156.6K 108.4K New —
DMI 2024-09-16 2024-09-16 ZBIO MOULDER LEON O JR CEO, Dir C - Cnv Deriv — +536.5K 164.5K New —
DM 2024-09-16 2024-09-16 ZBIO MOULDER LEON O JR CEO, Dir C - Cnv Deriv — -1.36M 0 -100% —
D 2024-09-16 2024-09-12 ZBIO MOULDER LEON O JR CEO, Dir A - Grant $0.00 +1.49M 1.49M New $0
DMI 2024-09-16 2024-09-16 ZBIO MOULDER LEON O JR CEO, Dir C - Cnv Deriv — -4.66M 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-09-16 C A 48,254 — 156,635 D — — (F4) On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
2 Common Common Stock 2024-09-16 C A 372,017 — 536,540 I — — (F4) On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
3 Common Common Stock 2024-09-16 C A 108,381 — 108,381 D See Footnote — — (F3) On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. (F2) Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
4 Common Common Stock 2024-09-16 C A 164,523 — 164,523 I See Footnote — — (F1) On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. (F2) Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
5 Derivative Series B Convertible Preferred Stock 2024-09-16 C D 418,996 — 0 D — · — to — 48,254 Common Stock (F4) On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
6 Derivative Series A Convertible Preferred Stock 2024-09-16 C D 941,088 — 0 D See Footnote — · — to — 108,381 Common Stock (F3) On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. (F2) Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
7 Derivative Stock Option (Right to Buy) 2024-09-12 A A 1,486,000 $0.00 1,486,000 D $17.00 · — to 2034-09-11 1,486,000 Common Stock (F5) The option vests as to 25% of the underlying shares of common stock on September 12, 2025, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal month installments over 36 months thereafter, subject to continued service.
8 Derivative Series B Convertible Preferred Stock 2024-09-16 C D 3,230,268 — 0 I — · — to — 372,017 Common Stock (F4) On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date.
9 Derivative Series Seed Convertible Preferred Stock 2024-09-16 C D 1,428,571 — 0 I See Footnote — · — to — 164,523 Common Stock (F1) On September 16, 2024, the shares of Series Seed Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. (F2) Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. Mr. Moulder disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.